|
Indian Pediatr 2010;47: 349-350 |
|
Antisnake Venom in a Neonate with Snake bite |
Geetanjali Jindal, Vidushi Mahajan and Veena R Parmar
From the Department of Pediatrics, Government Medical
College, Sector 32, Chandigarh, India.
Correspondence to: Dr Geetanjali Jindal, # 1203, Sector
32-B (GMCH, Doctor’s complex), Chandigarh, India.
Email:
[email protected]
Received: February 10, 2009;
Initial review: February 26, 2009;
Accepted: March 6, 2009.
|
Abstract
There is no report of the use of antisnake venom (ASV)
in the neonatal age group in literature. We report a 27 days old female
neonate who presented with neuroparalytic manifestations of snake bite
and was treated successfully with ASV. A total of 50 vials (500 mL) of
polyvalent antisnake venom were given as infusion in hourly aliquots of
50 mL, over 72 hours.
Key words: Antisnake venom, Neonate, Neuroparalytic, Snake
bite.
|
S nakebite is a common medical
emergency encountered in South Asia. In India alone, around 200,000 people
every year are bitten by snakes, out of which 15,000 die. Annual incidence
of snake bites in India is reported to be 0.16% with a mortality of 0.016%
per year(1). Majority of snake bites (90%) occur in males aged 11-50
years(2). To the best of our knowledge, there is no published case report
of snakebite in neonatal age group treated with ASV.
Case Report
A 27 days-old female neonate was brought with
inconsolable cry for 2 hours. Baby was sleeping on the bed with the
parents when mother woke up due to some noise at 1.30 am and saw a black
colored snake pass by. A drop of blood was noticed to ooze from left ear
and the child had severe retching. There was no history of bleeding from
any other site, abnormal movements or passage of dark colored urine or
decreased urination.
On admission, heart rate was 140 beats per minute,
respiratory rate - 60 breaths per minute, capillary filling time<3
seconds, peripheral pulses well palpable, blood pressure of 74/40 mmHg and
frothing was present. Systemic examination was normal. Child was admitted
with the diagnosis of snake bite and started on supportive management.
Twenty minutes post-admission, child suddenly developed
bradycardia, shallow breathing and cyanosis. Child was intubated and
started on synchronized intermittent mandatory ventilation (Galileo,
Hamilton Medical) with settings of PIP-22, PEEP-5, VR-40/min, FiO2-0.5,
Ti-0.4 sec. She required fluid resuscitation (normal saline 50 mL/kg) and
ionotropic support (dopamine at the rate of 10 mcg/kg/minute).
Neurological examination revealed Glassgow coma scale (GCS) E1M1V1,
generalized hypotonia, power grade zero and absent deep tendon reflexes.
Pupils were normal size and reacting to light. Doll’s eye movement was
present. Complete hemogram, renal function test and coagulogram (repeated
twice) were within normal limits. Total of 500mL (50 vials) of polyvalent
antisnake venom (Snake venom Antisera, Bharat Serums and Vaccines Limited)
was given in aliquots of 50mL as infusion over 1 hour over 72 hours.
Following administration of ASV, some flickering movements appeared after
24 hours. Child’s spontaneous respiratory efforts returned in 48 hours.
GCS improved to E4M5V5 and power grade became 4/5 in all the four limbs
after approximately 72 hours of ASV. No untoward reaction was noticed till
the end of infusion. Child was extubated by day 4. She was discharged in a
satisfactory condition after 7 days. No neurological or developmental
delay was observed after a follow up of 12 weeks.
Discussion
Although snakebite has been observed to occur in all
age groups, we have not encountered any case in the neonatal age group.
Lack of guidelines regarding ASV use in neonatal age group and its dosing
schedule were the problems in the management of this baby.
The clinical presentation of the baby fitted into
severe neurotoxic ophitoxemia. ASV was started within 4 hours of bite(3).
There are no clinical trials to determine the ideal dose but doses as high
as 1400ml (140 vials) have been used in adults(4). Our baby required 50
vials of ASV for complete recovery. The reversal of respiratory and
neuromuscular paralysis was used as the end point of antivenom therapy.
Higher doses of ASV may be required in neonates because of severe
envenomation due to small body size, inability to avoid the snake and
failure to raise alarm(5). Anti-cholinesterases were not used in the
present case; its role in neonates needs to be ascertained. As always,
supportive management viz maintainence of airway, oxygenation and
hemodynamic status formed the basis of successful outcome.
Contributors: GJ managed the case and did the
literature search, VM prepared the draft of the manuscript, VRP edited and
checked the final manuscript.
Funding: None.
Competing interests: None stated.
References
1. Hati AK, Mandal M, De MK, Mukherjee H, Hati RN.
Epidemiology of snake bite in the district of Burdwan, West Bengal. J
Indian Med Assoc 1992; 90: 145-147.
2. Hansdak SG, Lallar KS, Pokharel P, Shyangwa P, Karki
P, Koirala S. A clinico-epidemiological study of snake bite in Nepal. Trop
Doc 1998; 28: 223-226.
3. Paul VK. Animal and insect bites. In: Singh M (Ed).
Medical Emergencies in Children. 3rd ed. New Delh: Sagar Publications:
1993. p. 554-578.
4. Agrawal PN, Aggarwal AN, Gupta D, Behera D,
Prabhakar S, Jindal SK. Management of respiratory failure in severe
neuroparalytic snake envenomation. Neurol India 2001; 49: 25-28.
5. Fritts TH, McCoid MJ, Haddock RL. Risks to infants
on Guam from bites of the brown tree snake (Boiga irregularis). Am J Trop
Med Hyg 1990; 42: 607-611.
|
|
|
|